title: [Beta-blockers and statins in the context of asthma].
abstract: Asthma is a disease with a complex pathogenesis and differentiated clinical picture with airway inflammation in its background. Many cells and cell-released substances are engaged in the course of the disease. The basic treatment strategy in asthma is based on chronic administration of inhaled glucocorticosteroids (with a strong anti-inflammatory effect) and beta2-adrenoreceptor agonists (bronchodilatory effect). Much attention has been recently paid to the effects of other medicines on mechanisms important in the pathogenesis of asthma, including beta-blockers and statins. Many researchers have suggested a potentially useful role of some beta-blockers in chronic asthma therapy, particularly considering their effect on the pharmacodynamics of beta receptors in the bronchi. Moreover, statins, due to their anti-inflammatory and immunomodulatory effects, can also be useful in the management of asthma.
authors.affiliation: Klinika Alergologii i Chorób Wewnetrznych USK w Białymstoku. asiapaw@poczta.onet.pl
authors.forename: Joanna
authors.initials: J
authors.lastname: Pawlak
authors.forename: Ziemowit
authors.initials: Z
authors.lastname: Zietkowski
authors.forename: Anna
authors.initials: A
authors.lastname: Bodzenta-Łukaszyk
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D018927:Anti-Asthmatic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors